WINDTREE THERAPEUTICS INC /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $927.81 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-04-15
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $927.81, a 2109.07% increase from fiscal 2022.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $42.00, a 79.16% decline from fiscal 2021.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $201.50, a 3269.57% increase from fiscal 2020.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $5.98, a 40.32% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2023-12-31 | $927.81 10-K · filed 2025-04-15 | $1.03 10-K · filed 2024-04-16 |
| 2022-12-31 | $42.00 10-K · filed 2024-04-16 | |
| 2021-12-31 | $201.50 10-K · filed 2023-03-31 | $4.03 10-K · filed 2022-03-31 |
| 2020-12-31 | $5.98 10-K · filed 2022-03-31 | |
| 2019-12-31 | $10.02 10-K · filed 2021-03-29 | $3.34 10-K · filed 2020-04-03 |
| 2018-12-31 | $3.39 10-K · filed 2020-04-03 | |
| 2017-12-31 | $17.44 10-K/A · filed 2019-04-23 | |
| 2016-12-31 | $27.80 10-K · filed 2018-04-17 | $1.39 10-K · filed 2017-03-31 |
| 2015-12-31 | $10.48 10-K · filed 2017-03-31 | |
| 2014-12-31 | $25.48 10-K · filed 2016-03-29 | $1.82 10-K · filed 2015-03-16 |
| 2013-12-31 | $1.79 10-K · filed 2015-03-16 | |
| 2012-12-31 | $2.02 10-K · filed 2015-03-16 | $2.63 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |